Vaginal microbiota dynamics and fungal vulvovaginitis

Recent data suggests that Candida should no longer be considered the only pathogenic yeast in recurrent fungal vulvovaginitis, also known as recurrent vulvovaginal candidiasis. Nakaseomyces glabratus may play a key role, while restoring a lactobacillus-dominated microbiota warrants investigation as a way to prevent recurrence.

Between 70% and 75% of women will experience at least one episode of fungal vulvovaginitis—commonly called a vaginal yeast infection or vulvovaginal candidiasis—during their lifetime, with symptoms that may include itching, vulvar pain and abnormal vaginal discharge, and approximately 8% will develop a recurrent form,1 representing nearly 138 million women worldwide.2

Fungal vulvovaginitis

Infection of the vulva and vagina caused by an opportunistic yeast, primarily Candida albicans or Nakaseomyces glabratus.

A narrative review published in Current Fungal Infection Reports1 summarizes recent findings on the interaction between the vaginal microbiota, particularly Lactobacillus, and opportunistic yeasts of the genera Candida and Nakaseomyces. It aims to clarify their role in vaginal health and fungal vaginal infections. The authors advocate replacing the term “vulvovaginal candidiasis” with the broader term “fungal vulvovaginitis” to recognize the clinical role of other species, particularly Nakaseomyces glabratus (formerly Candida glabrata), in recurrent cases and certain cases of fungal vaginitis.

Vaginal microbiota

The collection of microorganisms that naturally colonize the vagina, whose composition and stability are closely associated with vaginal health.

Vaginal health

A balanced vaginal ecosystem characterized by an intact mucosa, a stable microbiota, and the absence of symptoms or pathological inflammation.

Vaginal infection

A general term for any bacterial, fungal or parasitic infection of the vaginal mucosa.

Imbalanced vaginal flora

Disruption of the usual protective dominance of lactobacilli, promoting dysbiosis and certain infections. 

Irritated vulva

A common symptom associated with vulvovaginitis (possible symptoms include redness, itching and a burning sensation).

Candida albicans and Nakaseomyces glabratus: two distinct mechanisms

C. albicans remains the most documented species, accounting for 63% to 70% of cases3 of fungal vulvovaginitis or vulvovaginal candidiasis. It invades the mucosa by transitioning to the hyphal form, a process mediated by adhesins and candidalysin, a toxin that activates the inflammasome.

Nakaseomyces glabratus behaves in the opposite way. Several Mexican cohorts cited in the review report that it clearly predominates in recurrent cases, in association with a decrease in Lactobacillus and an increase in Bifidobacterium. Rather than invade, it persists through biofilm formation, resistance to oxidative stress and immune evasion. This partly explains why conventional antifungals often fail and why the species involved should guide management.

Healthy vaginal microbiota associated with vaginal health

Species / associated microbial profile(s) : Lactobacillus crispatus (dominant), L. iners (may be present, with an ambivalent role).

Data reported in the review : L. crispatus dominance is generally associated with vaginal homeostasis and a low-inflammatory environment.

Recurrent bacterial vaginosis

Species / associated microbial profile(s) :Fewer lactobacilli and more anaerobes associated with bacterial vaginosis (BV), including Gardnerella vaginalis, Prevotella, Atopobium and Sneathia.

Data reported in the review : Recurrent BV may promote recurrent fungal infections through a pro-inflammatory environment; this proposed mechanism has not been formally demonstrated.

Sporadic fungal vulvovaginitis / vulvovaginal candidiasis

Species / associated microbial profile(s) : Candida albicans.

Data reported in the review : The main species involved in fungal vulvovaginitis (≈ 63–70% of reported cases).

Recurrent fungal vulvovaginitis – cited Mexican cohorts

Species / associated microbial profile(s) : Nakaseomyces glabratus (anciennement Candida glabrata).

Data reported in the review : Strongly associated with recurrent cases in the cited Mexican cohorts, along with changes in the vaginal microbiota

Lactobacillus dynamics and risk of recurrence

The loss of dominance of Lactobacillus crispatus — a species associated with vaginal health particularly through its role in acidifying the environment and producing antimicrobial compounds — in favor of less stable or dysbiotic microbial states is associated with reduced stability of the vaginal ecosystem and increased susceptibility to certain vaginal infections. However, L. iners has an ambivalent role: some strains stabilize the microbiota, while others promote dysbiosis and may even facilitate the filamentous growth of C. albicans in certain cases of vaginitis and fungal infection. 

The review also notes that recurrent bacterial vaginosis could trigger recurrent fungal vulvovaginitis by creating a pro-inflammatory environment that disrupts local immune tolerance to yeasts. This proposed mechanism has not yet been formally demonstrated but is consistent with the frequency of bacterial and fungal co-infections reported in the cited cohorts.

The male genital microbiota impact on women’s health

Learn more

Restorative approaches: preclinical data and current limitations

These treatment limitations and post-treatment recurrences have prompted research into approaches to restore the microbiota: vaginal microbiota transplantation (VMT), synthetic bacterial consortia transplantation (SBCT), and probiotics containing L. crispatus. In mice, these strategies have reduced inflammation and helped restore microbiota balance in models of bacterial vaginosis.In women, data on L. crispatus shows that vaginal colonization can be achieved after treatment for bacterial vaginosis. However, these studies focus exclusively on bacterial vaginosis. To date, no data supports the use of these restorative approaches for the treatment of fungal vulvovaginitis itself.

Vaginal microbiota transplantation (VMT)

An experimental approach that transfers the microbiota of a healthy donor to restore vaginal balance, under investigation as a potential treatment but not yet validated for fungal vulvovaginitis.

For recurrent cases, the data summarized in the review underscores the importance of considering species other than C. albicans, particularly N. glabratus. Restoring a lactobacillus-dominated microbiota is also a potential strategy for preventing recurrences, but it has yet to be clinically validated in fungal vulvovaginitis.

 

Sources

1. Ruiz-Higareda, Alvarez-Salas, García-Juárez et al. (2026). Vaginal Microbiota Dynamics as a Key Determinant of Pathogenesis in Fungal Vulvovaginitis. Current Fungal Infection Reports, 20:3. DOI 10.1007/s12281-026-00522-5.

2. Sobel JD, Sobel R. (2018). Current treatment options for vulvovaginal candidiasis caused by azole-resistant Candida species. Expert Opinion on Pharmacotherapy, 19(9):971-977. DOI 10.1080/14656566.2018.1476490.

3. Makanjuola O, Bongomin F, Fayemiwo SA. (2018). An update on the roles of non-albicans Candida species in vulvovaginitis. Journal of Fungi, 4(4):121. DOI 10.3390/jof4040121.

Summary
Off
Sidebar
Off
Migrated content
Désactivé
Updated content
Désactivé
Hide image
Off
News Off

Recurrent vaginal yeast infections: the microbiota connection

Could it be that recurrent vaginal yeast infections, also called recurrent vulvovaginal candidiasis, depend not only on the fungus responsible but also on the balance of the vaginal microbiota? A recent review examines this question and the approaches currently being explored. 

The vaginal microbiota

Between 70% and 75% of women will experience at least one vaginal yeast infection, or fungal vulvovaginitis, also called vulvovaginal candidiasis, in their lifetime. Nearly 8% will experience recurrent infections,1 representing nearly 138 million women worldwide.2

Fungal vulvovaginitis :

Infection of the vulva and vagina caused by an opportunistic yeast, primarily Candida albicans or Nakaseomyces glabratus, often called vulvovaginal candidiasis.

 

Most often caused by Candida albicans (63% to 70% of cases),3 it typically causes vulvar irritation, itching and unusual discharge. These symptoms are similar to those of another common vaginal infection, bacterial vaginosis, and certain other forms of vaginitis. A recent study1 examines an often-overlooked factor in these vaginal infections: the vaginal microbiota, a cornerstone of women’s health. 

Irritated vulva :

A common symptom associated with vulvovaginitis (redness, itching or a burning sensation). 

Vaginal infection :

A general term for any infection of the vaginal mucosa, whether bacterial, fungal or parasitic, that may be accompanied by unusual discharge.

Vaginal microbiota :

The community of microorganisms that live naturally in the vagina, whose composition and balance are associated with vaginal health.

Vaginal health :

A balanced state of the vaginal ecosystem, associated with healthy mucosa and the absence of symptoms or abnormal inflammation.

An overlooked ally in the vaginal microbiota

Candida albicans can be naturally present in the vagina without causing candidiasis or symptoms. Contrary to what you might think, Candida albicans, the yeast most often involved, can be naturally present in the vagina without causing candidiasis or symptoms, thanks to the balance of the surrounding microbiota. A protective bacterium, Lactobacillus crispatus, plays a key role: it makes the vaginal environment more acidic and produces substances that can limit the growth of certain microorganisms, including yeasts.Other bacteria, such as L. iners, play a more complex role: they sometimes help maintain stability but can also contribute to imbalance and certain vaginal infections.
Certain unsuitable or irritating hygiene products or recent antibiotic use can disrupt this balance. Once the balance is disrupted, dysbiosis, an imbalance in the vaginal flora, can develop and be associated with certain vaginal infections, including fungal infections such as candidiasis. 

Imbalanced vaginal flora :

Disruption of the usual protective dominance of lactobacilli, promoting certain vaginal infections and dysbiosis. 

What lives in the vaginal microbiota ?

Lactobacillus crispatus : bacterium often dominant in a healthy vaginal microbiota—helps maintain acidity and limit the growth of certain microorganisms.

Lactobacillus iners : ambivalent role—sometimes stabilizing, sometimes contributing to imbalance depending on the strain.

Candida albicans : yeast that may naturally be present in the vagina without causing symptoms but can proliferate and cause candidiasis.

Nakaseomyces glabratus (formerly Candida glabrata) : less conspicuous yeast, more often associated with recurrent yeast infections.

Gardnerella vaginalis : a bacterium commonly associated with bacterial vaginosis, a dysbiosis distinct from candidiasis. A possible link to certain recurrent fungal infections is currently being discussed.

Why yeast infections keep coming back

For recurrent candidiasis, the study also points to another yeast that is less well known than Candida albicans but just as involved: Nakaseomyces glabratus (formerly Candida glabrata). It does not attack tissues in the same way. Instead, it persists through several mechanisms, including biofilm formation and immune evasion, which may contribute to recurrences and make treatment more difficult. The authors raise another possibility: recurrent bacterial vaginosis, characterized by an imbalance in the vaginal microbiota, could disrupt the local balance and, in turn, promote the development of a yeast infection and certain recurrences. The two vaginal conditions may therefore be more closely linked than previously thought, particularly in certain mixed or successive infections.

Treatment for vaginal infections based on basil essential oil

Learn more

If symptoms recur despite following treatment as directed, it is best to seek medical care to confirm the diagnosis and adjust treatment rather than repeatedly self-treat with antifungal medications. Restoring lasting balance to the vaginal microbiota, particularly through still-experimental approaches involving microbiota transplantation or modulation, is another avenue of research. Its effectiveness against fungal vulvovaginitis remains to be demonstrated.

Vaginal microbiota transplantation (VMT) :

An experimental approach involving the transfer of microbiota from a healthy donor to restore vaginal balance. Its value as a treatment for fungal vulvovaginitis remains to be confirmed.

Sources

1. Ruiz-Higareda, Alvarez-Salas, García-Juárez et al. (2026). Vaginal Microbiota Dynamics as a Key Determinant of Pathogenesis in Fungal Vulvovaginitis. Current Fungal Infection Reports, 20:3. DOI 10.1007/s12281-026-00522-5.

2. Sobel JD, Sobel R. (2018). Current treatment options for vulvovaginal candidiasis caused by azole-resistant Candida species. Expert Opinion on Pharmacotherapy, 19(9):971-977. DOI 10.1080/14656566.2018.1476490.

3. Makanjuola O, Bongomin F, Fayemiwo SA. (2018). An update on the roles of non-albicans Candida species in vulvovaginitis. Journal of Fungi, 4(4):121. DOI 10.3390/jof4040121.

Summary
Off
Sidebar
On
Migrated content
Désactivé
Updated content
Désactivé
Hide image
Off
News Off

Could rebalancing your gut microbiota help alleviate depression ?

Le microbiote intestinal pourrait-il influencer notre santé mentale en agissant sur notre énergie ? Une étude chez l’humain et la souris explore ce lien entre bactéries intestinales, métabolisme et symptômes dépressifs. 

The gut microbiota
Rééquilibrer son microbiote pour sortir de la dépression ?

What if restoring a healthy gut microbiota could help you alleviate depression by giving your body an energy boost?

Depression doesn’t just affect mood and cognitive function. It frequently goes hand in hand with changes in energy metabolism and gut microbiota, as confirmed by a study¹ involving 100 patients with major depressive disorder and 68 healthy controls. 

Major depressive disorder

Major depressive disorder (MDD) is a highly disabling psychiatric condition with a substantial global burden, exhibiting a lifetime prevalence of 10%–20%.¹

1,5 Depression is about 1.5 times more common among women than among men.²

10% Worldwide, more than 10% of pregnant women and women who have just given birth experience depression (perinatal depression).²

A link between microbiota, metabolism, and depression

The results are clear: in people with depression, several pathways involved in energy production are disrupted, with some metabolites present in excess—such as lactate, glutamate, and arginine—and others in lower-than-normal levels, including glucose and ornithine. These metabolic disturbances are associated with more severe symptoms, including increased anxiety, more pronounced depressive symptoms, and greater cognitive difficulties.

But that’s not all. The authors also found differences in the gut microbiota of people with depression: a dysbiosis is present, involving around 100 bacterial species that are either more or less abundant than in stool samples from healthy controls. 

What if everything were connected? Among these microorganisms that are over- or underrepresented in the gut, several may influence our energy metabolism and, in turn, negatively affect our mood. Or, conversely, they could improve our mental health—provided we give good bacteria in our gut a little boost. But before considering such an approach, researchers first needed to establish a causal relationship. That has now been demonstrated.

4% An estimated 4% of the population experience depression, including 5.7% of adults (4.6% among men and 6.9% among women), and 5.9% of adults aged 70 years and older.²

332 million Approximately 332 million people in the world have depression.³

3rd Suicide is the third leading cause of death in 15–29-year-olds.²

A mouse experiment to test causality

Researchers subjected mice to chronic stress that induced depressive-like behaviors. As observed in patients with depression, the mice developed alterations in both their gut microbiota and energy metabolism.

The study focuses on the microbiota—the gut bacterial community—and its links to metabolism and mental health.
Previous studies had already identified changes in the gut bacteria of patients with major depressive disorder, but the links between these changes and metabolism had remained largely correlational.

The researchers then transplanted the mice’s own fecal microbiota, collected before they were exposed to chronic stress, back into the animals after they had developed depression-like behaviors. Following this procedure, known as an autologous fecal microbiota transplant (each mouse received its own gut microbiota), several metabolic abnormalities were corrected, and the mice showed improvements in their mental health. Mitochondrial function—which provides energy—was also restored in brain regions involved in mood and memory.

"The transplant reintroduced bacteria that had been present in the gut before exposure to the stressor.”

“From a mental-health perspective, these findings add to the growing evidence supporting the importance of the gut–brain axis. However, they do not demonstrate that interventions targeting this axis can treat depression in humans.”

What about humans?

So far, this causal relationship has only been demonstrated in animals. Further studies are needed to determine whether the same mechanism exists in people with major depressive disorder and, above all, whether modulating the gut microbiota could one day have therapeutic potential. In the meantime, to give your mood a boost, you can start by taking care of your gut microbiota. How? Through diet, for example, by choosing citrus fruits and cutting out soda.

Three examples to help you understand

Reducing excess (toxic) lactate

In people with depression, chronic stress can impair mitochondrial function—the mitochondria being the powerhouses of our cells—and cause brain cells to switch to an alternative energy-producing pathway known as anaerobic glycolysis. This can lead to an abnormal and harmful buildup of lactate in the blood and brain. This excess of lactate may contribute to depressive behaviors and memory deficits. However, the gut bacterium Anaerostipes hadrus may alleviate anxiety and depression by reducing brain lactate levels, thus allowing the mitochondria to resume their normal function and reversing this anaerobic glycolytic shift.

Reducing excess (toxic) glutamate

In people with depression, glutamate is thought to accumulate at abnormally high levels in the blood and brain. These elevated glutamate levels are thought to interfere with brain energy metabolism and may exacerbate depressive symptoms. The gut bacterium Anaerostipes hadrus may play a potentially beneficial role in improving depression and anxiety: it seems to have a protective effect by reducing certain key metabolites, including glutamate, as well as lactate and isocitric acid.

Increasing ornithine (a protective agent) when levels are low

In people with depression, ornithine levels are believed to be very low in the blood and brain. This deficiency could contribute to the accumulation of toxic metabolites by impairing ammonia detoxification and increasing glutamate production. It may also deprive the brain of neuroprotective compounds, since ornithine serves as a precursor for their synthesis. Together, these changes could increase vulnerability to depression, fatigue, and cognitive decline. However, several intestinal bacteria, such as Dorea formicigenerans and Eubacterium ramulus , appear to be major sources of ornithine for the host. 

Sources

1. Lei P, Qi Z, Ma Q et al. Gut microbiota reshapes host energy metabolism to modulate depressive behaviors. Gut Microbes. 2026 Dec 31;18(1):2662556.
2. https://www.who.int/news-room/fact-sheets/detail/depression. 
3. 2021 Global Burden of Disease. 

Summary
Off
Sidebar
Off
Migrated content
Désactivé
Updated content
Désactivé
Hide image
Off
News Off

Depression: could the microbiota-metabolism axis be involved?

What if the gut microbiota contributes to depression by disrupting energy metabolism? A multi-omic study in humans, complemented by a mouse model, reveals a potential link between the gut microbiota, metabolites, and depressive phenotypes.

 Dépression : un axe microbiote-métabolisme en cause ?

Major depressive disorder (MDD) is not limited to affective and cognitive symptoms; it is also associated with substantial disturbances in energy metabolism, including blood glucose dysregulation, mitochondrial dysfunction, and alterations in key metabolic pathways such as glycolysis, the Krebs cycle, and amino acid metabolism. At the same time, gut dysbiosis is frequently observed in patients with MDD, with alterations in specific bacterial species, including Faecalibacterium prausnitzii and Escherichia coli, that may indirectly influence host metabolic pathways. This led the researchers1 to ask: could the gut microbiota influence the host’s energy homeostasis and in turn, alleviate depression? 

Major Depressive Disorder (MDD)

Major Depressive Disorder (MDD) is a highly disabling psychiatric condition with a substantial global burden, exhibiting a lifetime prevalence of 10%–20%.1

A microbiota-metabolites-depressive phenotype axis

Analysis of serum and fecal samples from 100 patients with depression and 68 healthy controls revealed significant disruptions in key energy metabolism pathways in individuals with depression: 14 metabolites were significantly altered, including lower serum levels of glucose, ornithine, AMP, and cyclic AMP, and higher levels of lactate, glutamate, arginine, citrulline, and isocitrate. Several of these metabolites were also associated with measures of depression, anxiety, and cognitive function, suggesting a potential link between these metabolic alterations and the severity of depressive symptoms.

Most importantly, the authors identified 92 bacterial species that differed significantly in individuals with depression, including 50 that were overrepresented and 42 that were underrepresented, particularly within the Firmicutes phylum. The researchers also identified 36 bacterial species whose abundance was potentially associated with mitochondrial fatty acid synthesis, ketogenesis, and amino acid metabolism. Among these, 28 species appeared to be involved in the relationship between the gut microbiota, energy metabolites, and mood, cognitive function, and anxiety. These findings thus point to a potential “gut microbiota–metabolites–depressive phenotype” axis, in which certain bacterial metabolites act as mediators.

332 million Approximately 332 million people in the world have depression.²

Preclinical evidence supporting a causal role for the gut microbiota

As is often the case in microbiota research, an important question remained: were these findings simply correlational, or could the gut microbiota play a causal role? To investigate this, the researchers first collected samples of the gut microbiota from mice and then subjected them to 14 days of chronic stress, which induced depressive-like behaviors (including reduced sucrose preference and increased immobility) as well as impaired memory. An autologous fecal microbiota transplantation (FMT) was performed after each episode of stress. FMT reduced depressive-like behaviors and improved memory, while also restoring the composition and function of the gut microbiota. However, the intestinal barrier remained impaired. Most importantly, FMT corrected several metabolic disturbances—including alterations in glucose, lactate, glutamate, and the ornithine cycle—and restored mitochondrial structural integrity in the prefrontal cortex and hippocampus of the mice. According to the authors, these findings highlight the role of the gut microbiota in regulating energy metabolism in depressive disorders. 
Although the experiment has so far been conducted only in mice, they raise an intriguing question: could early autologous FMT one day become a therapeutic approach for depression in humans? This remains an important avenue for future research.

Modulation of the microbiota by FMT: controversial results

Learn more

In the meantime, maintaining a balanced diet that includes some citrus fruits and engaging in regular physical activity such as running, may be beneficial.

Summary
Off
Sidebar
On
Migrated content
Désactivé
Updated content
Désactivé
Hide image
Off
News Off

Can AI identify promising vaginal probiotic strains?

We often consider Lactobacillus crispatus a hallmark of vaginal health. But not all strains share the same functional properties. A new study shows how machine learning could help identify strains with the most promising in vitro probiotic potential.

Can AI identify promising vaginal probiotic strains?

When considering a vaginal probiotic, we may read a species name off the label and assume it carries a defined benefit. A new study 1 challenges that assumption directly: does the functional potential of Lactobacillus crispatus belong to the species as a whole, or to individual strains we've been lumping together far too generously?

One species, forty-seven versions of it

The team collected 1,126 bacterial isolates from vaginal swabs collected from 36 healthy women aged 18 to 30. Of these, 639 turned out to be Lactobacillus crispatus. Phylogenomic analysis grouped these 639 isolates into 47 distinct clades, revealing substantial diversity within the species. Across the 639 isolates, the pangenome contained 4,482 gene families, of which 1,579 belonged to the core genome. This highlights meaningful genomic diversity within L. crispatus, despite an overall conserved genomic structure.

This diversity isn't just academic: strains differed in the presence and copy number of genes encoding pullulanase (PulA), an enzyme involved in glycogen degradation that may help L. crispatus exploit this carbon source in the vaginal environment. Existing general probiotic screening tools may struggle to capture these strain-level differences. When the researchers ran the strains through an existing tool called iProbiotics, nearly every one scored well, averaging 97.58%, which illustrates the challenge of distinguishing strain-level functional potential using existing general probiotic prediction approaches.

Strain-level functional potential: the measurable capacity of one isolate, not one species, to acidify, produce lactic acid and H2O2, and inhibit pathogens. The 67 strains tested varied fivefold in lactic acid output alone.

Pullulanase (PulA): an enzyme involved in glycogen degradation. Its presence may help L. crispatus use vaginal glycogen and adapt to the vaginal environment (supports colonisation and sustained acidification).

The phenotypes that distinguish higher-performing strains

The researchers then tested 67 representative strains on five in vitro traits that may matter clinically and considered relevant to vaginal probiotic potential: how well they grow, how much they acidify their environment, how much lactic acid and hydrogen peroxide they produce, and how well they block vaginal pathogens. The results varied widely. Lactic acid output ranged from 2.02 to 10.29 g/L, and hydrogen peroxide levels from 9.39 to 18.3 µmol/L, even though all the strains belonged to the same species. Final pH ranged from 3.8 to 4.45, so every strain made its environment more acidic, just not to the same degree.

Strains also differed in how well they blocked
Gardnerella vaginalis, a bacterium linked to bacterial vaginosis : the inhibition zone averaged 15.35 mm but varied by several millimeters from one strain to the next. The researchers combined these five measurements into a single score, giving the heaviest weight, 30%, to how well a strain fought off BV-related pathogens. They then split the strains at the median into a higher functional-potential group, labeled Lcris-SFS, and a lower functional-potential group.. The three top-performing strains are now being tested in animals and in early clinical studies.

Lcris-SFS: labels for strains scoring above or below the median on the composite functional score. They rank functional potential and are not a judgement of safety.

Vaginal dysbiosis: a shift away from a Lactobacillus-dominated vaginal microbiota toward a more diverse community enriched in anaerobic bacteria. Bacterial vaginosis is a common dysbiotic state.

A model that reads function from the genome

To avoid months of lab culture work, the researchers built a computer model called VLCPredictor. It reads short DNA snippets from each strain's genome, narrows 349,184 of these snippets down to the 534 most informative ones, and uses that pattern to predict a strain’s functional potential, helping prioritize candidates for further experimental testing. Eight prediction methods were tested, and the best performing model, a random forest, achieved a mean AUC of 0.742 for distinguishing strains with higher versus lower functional potential.. Applied to 103 published genomes, the model flagged about 76% of strains from healthy women as having higher predicted functional potential, compared with only 31% of strains from women with bacterial vaginosis. The model isn't perfect: it was trained on genomes from a single region and ethnic group, and only 16 genomes came from women with bacterial vaginosis, so it still needs more validation. The importance of strain-level selection is also illustrated by previous clinical studies cited by the authors: one L. crispatus-based probiotic reduced bacterial vaginosis recurrence following antibiotic treatment, whereas another Lactobacillus-based probiotic combination did not improve cure rates in a separate trial. 

Vaginal lactobacilli's anti-inflammatory superpowers

Learn more

The clinical message is not that genomic prediction can already select a probiotic for an individual patient. Rather, this study reinforces the importance of strain-level characterization: belonging to a health-associated species such as L. crispatus does not guarantee identical functional properties. VLCPredictor could help researchers prioritize promising candidates, but in vivo and clinical validation remain essential before translating these predictions into practice.

Summary
Off
Sidebar
On
Migrated content
Désactivé
Updated content
Désactivé
Hide image
Off
News Gynecology Obstetrics Off

Oral microbiome dynamics during travel : environmental exposure, dysbiosis, and resilience

The ENT microbiota
Evolución de la microbiota bucal durante los viajes: exposición ambiental, disbiosis y resiliencia

 1. How much do people travel each year ?

According to the European Commission, EU residents aged 15 years and older made nearly 1.2 billion tourism trips with overnight stays in 2024, corresponding to approximately three trips per person per year.1 This frequency of travel is biologically significant, as repeated movement between environments creates repeated opportunities for microbial exposure and short-term ecological disruption. While travel-associated changes in the gut microbiome and the clinical syndrome of travelers’ diarrhea are well documented, the oral microbiome—including saliva-, tongue-, and plaque-associated communities—has received far less attention, despite serving as a primary interface between the host and the external environment. 

Travel repeatedly perturbs the microbiome through exposure to new environments, diets, and water sources, yet the oral microbiome remains far less studied than the gut despite being the first point of contact.

2. Why travel should reshape the oral microbiome

The oral cavity is continuously exposed to the external environment, making it particularly sensitive to rapid lifestyle and environmental changes. Although oral microbial communities are generally stable within individuals, they respond to shifts in diet, oral hygiene practices, circadian rhythms, stress, and immune status. Oral health depends on community balance (homeostasis), and dysbiosis—disruption of community structure or function—is associated with both oral and systemic disease.2
Travel concentrates multiple perturbations simultaneously, including exposure to new environments, water sources, dietary patterns, and social contacts,3-4 all of which can influence resident microbial communities. As the entry point to the gastrointestinal tract, the oral cavity may also influence downstream microbial ecology. Large, multi-country studies have shown that oral microbes can transmit to and colonize the gut more frequently than previously appreciated, even in healthy individuals.5

Travel-induced microbiome disruption is often transient but not always fully reversible, with microbial and resistance-related changes persisting beyond clinical symptom resolution.

3. When travel introduces new microbes: dysbiosis, food poisoning, and diarrhea

A well-recognized risk of travel is acute gastrointestinal infection, often caused by food- or water-borne pathogens, which can coincide with microbial community disruption. Longitudinal studies show that microbiome composition shifts during travel and that diarrheal episodes can destabilize community structure and increase antimicrobial resistance gene abundance for weeks.6-7 Travel is also associated with colonization by multidrug-resistant organisms, particularly among individuals who experience travelers’ diarrhea.6 Clinically, most uncomplicated cases of travelers’ diarrhea resolve within days. However, microbiome studies suggest only partial resilience: microbial composition often trends back toward baseline after return, but recovery may be delayed or incomplete. Notably, travel-associated antimicrobial resistance signatures can persist for weeks following the initial disruption in some cohorts.6, 8-9

Traveling shapes our lives...but also our microbiota and antibiotic resistance

Learn More

4. The underexplored questions: acclimation time, stability, and permanence

Despite growing interest in travel-related microbiome dynamics, direct longitudinal sampling of the oral microbiome during travel remains rare. Time-series studies of the gut microbiome in non-travel settings reveal substantial day-to-day variability even under stable conditions, highlighting the need for dense longitudinal sampling to distinguish normal temporal variation from true travel-induced effects.4

Leveraging a year-long international gap-year program, Dr. Wendy Lin is tracking oral microbiome changes in a student cohort as they travel across seven regions, including the United States, Brazil, France, Turkey, Kenya, India, and China. This study aims to address fundamental questions that remain poorly characterized for the oral microbiome:

  • How long does it take for the oral microbiome to acclimate to a new environment?

  • Is the travel-associated oral microbiome stable or highly dynamic?

  • How quickly does the oral microbiome revert to baseline after returning home?

  • Do newly introduced taxa or strain-level variants persist long-term?

The timing, stability, and long-term persistence of travel-associated changes in the oral microbiome remain largely unknown.

Conclusion

Travel predictably alters environmental exposures and dietary patterns, creating a natural experiment for studying human microbiome ecology. Evidence from gut microbiome studies of travelers demonstrates rapid compositional shifts during travel and additional disruption during diarrheal illness, often followed by delayed or incomplete recovery. The oral microbiome—despite being the first point of contact for food, water, and environmental microbes—remains comparatively undercharacterized in this context. Longitudinal studies of traveling cohorts with dense oral sampling have the potential to answer foundational questions about microbial acclimation, stability, and long-term persistence, and to determine whether travel leaves lasting microbial imprints after individuals return home. 

Summary
Off
Sidebar
On
Migrated content
Désactivé
Updated content
Désactivé
Hide image
Off
News Off

Coffee and decaf: what effects do they have on the microbiota?

According to a new exploratory study, caffeinated coffee is not the only brew that affects the brain. Decaf may have an impact too. And your gut microbiota could be the missing link.

The gut microbiota

It is now well established that coffee can influence cognitive function, affecting attention, alertness, memory, and the body’s response to stress. Yet the underlying mechanisms remain largely unclear. Are they mediated by the microbiota? And perhaps more intriguingly, is caffeine really the key compound behind coffee’s effects on the brain—or is there more to the story?

-27 % The estimated reduction in the risk of Alzheimer's disease among coffee drinkers.²

3rd most popular beverage in the world Coffee is said to be the third most widely consumed beverage in the world, after water and tea.³

2 billion That's the number of cups of coffee consumed worldwide every day.³

Understanding the links between coffee, the gut, and cognition

This is a legitimate question. Several nutritional studies have shown that coffee, through its bioactive compounds (chlorogenic acids, melanoidins, and other polyphenols), can significantly modulate the composition of the gut microbiota. Moreover, the gut microbiota and the brain are in constant communication through the microbiota-gut-brain axis. Beyond caffeine, this axis may help explain some of coffee’s effects on health.

To test this hypothesis, researchers in Ireland recruited 62 healthy adults who had not recently taken probiotics, prebiotics, or antibiotics. Half were habitual coffee drinkers, consuming three to five cups a day, while the other half did not drink coffee. The coffee drinkers first abstained from coffee for two weeks before resuming their usual habit for three weeks. During this period, they consumed either regular or decaffeinated coffee, while keeping their usual diet unchanged. The aim was to disentangle the effects of caffeine from those of coffee’s other compounds.

Throughout the study, the researchers collected stool, urine, and blood samples and assessed participants’ cognitive and behavioral performance at several time points, while also monitoring their dietary intake.

The surprising effect of coffee on the microbiota

Learn more

Positive effects on mood and cognition

Published in Nature Communications,¹ the study found that habitual coffee drinkers exhibited notable differences in their gut microbiota. In particular, they showed a higher abundance of Firmicutes CAG:94, a bacterial strain that has been associated with positive emotional states in women.

Following a period of coffee abstinence and subsequent reintroduction, both caffeinated and decaffeinated coffee were found to affect seven specific bacterial strains in the gut microbiota, without altering overall microbial diversity. 

The effects on the brain were equally intriguing. Reintroducing coffee—regardless of its caffeine content—was associated with several beneficial outcomes, including reductions in:

  • perceived stress,
  • experienced depressive symptoms,
  • impulsivity, defined as the tendency to act quickly without considering the potential consequences.

However, only caffeinated coffee was associated with reduced anxiety, improved cognitive performance, and greater resilience to stress.

Perhaps more surprisingly, the consumption of decaffeinated coffee—but not caffeinated coffee—was associated with improved episodic memory, increased physical activity, and better sleep quality. 

The microbiota: a likely mediator between coffee and the brain

Analysis of stool samples from coffee drinkers revealed that, before the abstinence period and compared with non-drinkers, they had lower levels of indole-3-propionic acid–a metabolite involved in nervous system function–, and GABA, a neurotransmitter that plays an important role in anxiety and cognitive function.

The researchers also found that levels of five coffee-related metabolites (theophylline, hippuric acid, 1,7-dimethylxanthine, and two others) were strongly associated not only with cognitive and behavioral outcomes, but also with numerous species of gut bacteria.

According to the researchers, these fecal metabolite profiles primarily reflect the metabolism of coffee’s various polyphenols, regardless of whether the coffee is caffeinated or decaffeinated. Decaf is therefore clearly more than just 'placebo coffee'.

Overall, the findings of this far-reaching study point to a clear association between coffee consumption, gut bacteria, metabolites, and cognitive and behavioral outcomes. They therefore lend further support to the hypothesis that the gut-microbiota-brain axis may play a role in the effects of coffee. We can therefore conclude that there are several potential health benefits, but this is certainly not a free pass to go overboard with coffee either. As we know, excessive consumption can also have adverse effects on health.

Further research will be needed to move beyond these associations and determine whether there is a true causal relationship between coffee, the gut microbiota, metabolites, and cognitive and behavioral outcomes.

Summary
Off
Sidebar
On
Migrated content
Désactivé
Updated content
Désactivé
Hide image
Off
News Off

When an oral bacterium turns immune cells into killers

We've long blamed Fusobacterium nucleatum for fueling colon cancer. New research shows it can also pull immune cells into the tumor and switch them into killers. Whether that happens depends on a gene your patient carries.

When an oral bacterium turns immune cells into killers

Neutrophils in colorectal tumors have a bad reputation, and so does Fusobacterium nucleatum. A new study1 puts the two together and finds something unexpected: the bacterium draws neutrophils into the tumor and switches them on to kill it. Whether that happens in your patient comes down to one receptor.

Tumor-associated neutrophils (TANs)

Neutrophils recruited into the tumor microenvironment. Long assumed to be immunosuppressive, they are shown here to kill CRC cells once the right bacterial signal reaches them.1

Not every gut bacterium recruits neutrophils the same way

Of the two bacteria most common in colorectal tumors, only F. nucleatum pushed tumor cells to release neutrophil-attracting signals, and drew far more neutrophils toward it in lab tests than Bacteroides fragilis did. In mice, F. nucleatum raised neutrophil levels inside the tumor; B. fragilis did not. Direct contact matters too: within five minutes, F. nucleatum latched onto up to 25% of circulating neutrophils and switched on an activation marker that peaked by three hours.

Links between gut microbiota and colorectal cancer are confirmed

Learn more

One receptor flips the switch, and it isn't TLR4

Neutrophils exposed to F. nucleatum released a cocktail of antimicrobial and tumor-killing compounds. Their conditioned media killed colon cancer cells in the lab and slowed tumor growth in mice when injected directly into it; B. fragilis-conditioned media did nothing. Blocking TLR4 stopped the activation marker from appearing but left the killing intact. Blocking Siglec-5/14 did the opposite: killing stopped. Siglec-14 is the one that binds the bacterium tightly, while its partner Siglec-5 barely does. Unlike most of its receptor family, which calms neutrophils down, Siglec-14 switches them on instead.

Siglec-14

A sialic-acid-binding immunoglobulin-like lectin on neutrophils. It binds F. nucleatum LPS and is required for cytotoxicity; blocking it abolishes killing without preventing activation.1

A common gene variant may explain the conflicting outcomes data

Patients carrying two copies of a common SIGLEC14 gene variant have neutrophils that still respond to F. nucleatum but can't kill: the more copies of the variant, the weaker the response. That variant is present in under 10% of Europeans but up to 70% of East Asians, which may explain the split literature: European and US cohorts link neutrophil infiltration to better survival, Chinese cohorts to worse. Mice lack the activating receptor entirely, which is likely why animal studies have painted F. nucleatum as purely harmful. In one 444-patient sample, high neutrophil markers predicted longer survival, but only in tumors that also carried F. nucleatum. In a large public gene-expression database (The Cancer Genome Atlas), the 31 patients whose tumors lacked SIGLEC14 did worse than the 351 who had it.

This is a biomarker question before a prescribing one. The next time the evidence on neutrophil infiltration in CRC looks irreconcilable, the missing variables may be which bacteria occupy the tumor and which Siglec-14 allele the patient inherited.

Summary
Off
Sidebar
On
Migrated content
Désactivé
Updated content
Désactivé
Hide image
Off
News Off

Menstrual cup: reassuring findings regarding infection risk

Among women who use menstrual cups during their periods, current evidence does not suggest an increased risk of genital infections. On the contrary, available findings point to a possible reduction in bacterial vaginosis and STIs, while also indicating that a healthy vaginal microbiota is maintained.

Coupe menstruelle : résultats rassurants sur les infections

A menstrual cup is an intravaginal device that comes in different sizes, depending on the model. Unlike an IUD, it is not inserted into the uterus. Instead, it sits in the vagina and collects menstrual blood. As a reusable menstrual product, the menstrual cup has progressively become more popular alongside conventional products such as tampons, as well as newer alternatives such as period underwear. However, despite the growing use of menstrual cups for menstrual hygiene, their potential effects on the vaginal microbiota, infections, and reproductive health have not yet been extensively studied.
This underlines the importance of this systematic review and meta-analysis1 that investigated the relationship between menstrual cup use for menstrual protection and reproductive tract infections (RTIs), sexually transmitted infections (STIs), and the vaginal microbiota.

1.8 billion Every month, almost 1.8 billion people worldwide menstruate.¹

65 days On average, menstruation accounts for a total of 65 days per year.¹

18 % In the United States, 18% of women reported using a menstrual cup.¹

No increased risk of infection 

A total of 11 studies were included in the review, 8 of which were published after 2019. Together, they involved 10,268 adult and adolescent women from Africa (Kenya and Tanzania), the Americas (Brazil and the United States), and Europe (France, Belgium, and Denmark). One important limitation is that only three of the studies were considered to be of high quality. This limits both the overall scope of the review and the robustness of the results.Despite this limitation, the findings are broadly reassuring—and even encouraging—with regard to the use of menstrual cups: no increased risk of infection was observed among menstrual cup users for the infections evaluated. 
The findings actually point in the opposite direction. Observational studies and randomized trials conducted across three continents found a lower prevalence of bacterial vaginosis among menstrual cup users (around -20%).
Menstrual cup use also appears to be associated with a lower prevalence of STIs (- 26 %) than other menstrual products and protection methods. This finding comes from two randomized controlled trials conducted among young women in Kenya. One trial also suggested a possible reduction in the risk of HSV-2 (herpes simplex virus type 2) infection, although the difference did not quite reach statistical significance.

Bacterial vaginosis: sexual transmission & genomic insights

Learn more

A beneficial effect on the vaginal flora?

Regarding the vaginal microbiota, menstrual cup users appear more likely to have a community-state type I (CST-I) microbiota, characterized by a predominance of Lactobacillus crispatus. This was observed in populations from the three European countries and in Kenya. This potential benefit may be partly explained by how the cup works. By collecting menstrual blood in the upper part of the vagina, the cup may reduce the exposure of the vaginal microbiota to iron-rich blood, which can promote the growth of Gardnerella vaginalis and L. iners. Menstrual cups may therefore help preserve a healthy vaginal microbiota dominated by L. crispatus, a profile associated with greater protection against vaginal dysbiosis and certain STIs. No cases of toxic shock syndrome were reported among menstrual cup users in the two studies that provided this information.
Overall, the authors conclude that menstrual cups represent an affordable, easy-to-implement, and sustainable option that could help reduce the burden of preventable gynecological conditions while supporting menstrual and intimate hygiene.

Summary
Off
Sidebar
On
Migrated content
Désactivé
Updated content
Désactivé
Hide image
Off
News Off

Menstrual cup: a potential benefit for vaginal health ?

Contrary to some concerns, using a menstrual cup does not appear to increase the risk of genital infections. On the contrary, its use seems to be associated with a lower prevalence of bacterial vaginosis and STIs, as well as a vaginal microbiota that is more often in optimal condition.

The vaginal microbiota
Coupe menstruelle : un atout pour la santé vaginale ?

In recent years, menstrual cups have become an increasingly popular menstrual product. Reusable, affordable, and environmentally friendly, they are available in different sizes depending on the model. Unlike an IUD, a menstrual cup does not need to be inserted into the uterus. Instead, it sits in the vagina, where it simply collects menstrual blood. But how does using a menstrual cup affect menstrual hygiene, the vaginal microbiota, and the risk of infection when it remains in the vagina for up to 12 hours?
A comprehensive review of the literature,1 compiling the findings from 11 studies involving more than 10,000 participants across Africa, Europe, Brazil, and the United States, offers some reassuring answers.

1.8 billion Every month, almost 1.8 billion people worldwide menstruate.¹

65 days On average, menstruation accounts for a total of 65 days per year.¹

Not more infections… in fact, fewer

First finding: no increased risk of infection was observed among menstrual cup users. In fact, several findings point to a potential protective effect. For instance, some studies found that women using a menstrual cup had 21% lower incidence of bacterial vaginosis than those using other menstrual products, particularly tampons or pads.
A similar finding was observed for sexually transmitted infections (STIs). Two trials conducted among young women in Kenya found a lower risk of STIs
among menstrual cup users. The risk of HSV-2 (herpes simplex virus type 2) infection may also be reduced, although this finding has not yet been confirmed.

18 % In the United States, 18% of women reported using a menstrual cup.¹

12 heures Menstrual cup can be used for up to 12 h prior to being emptied, carefully cleaned and reinserted.¹

An ally of the vaginal microbiota

These potential benefits may be related to the menstrual cup’s protective effect on the vaginal microbiota. Menstrual cup users are more likely to have a microbiota dominated by Lactobacillus crispatus, a bacterial species considered a marker of good vaginal health and associated with protection against vaginal dysbiosis, bacterial vaginosis, and certain STIs. No cases of toxic shock syndrome were reported among menstrual cup users in the two studies that provided this information.
Why does this happen? The authors put forward a simple hypothesis: unlike tampons or pads, the menstrual cup collects menstrual blood in the upper part of the vagina. As a result, the vaginal microbiota may have less exposure to iron-rich blood, an environment that can favor the growth of bacteria such as Gardnerella vaginalis and Lactobacillus iners, which are often associated with an imbalance in the vaginal flora.

Female anatomy, microbiotas and intimate hygiene

Learn more

Promising findings… pending further confirmation

The authors remain cautious: the studies are still scare, involve comparatively small numbers of women, and are not always of high quality. Based on the current evidence, the review provides a reassuring message: menstrual cups do not appear to pose a risk to your vaginal microbiota and may, in fact, have a beneficial effect.

Summary
Off
Sidebar
On
Migrated content
Désactivé
Updated content
Désactivé
Hide image
Off
News Off